N

Novavax

NVAX

12.560
USD
-0.25
(-1.95%)
مغلق
حجم التداول
156,177
الربح لكل سهم
0
العائد الربحي
0
P/E
-4
حجم السوق
1,624,950,436

أصول ذات صلة

ABBV
4.380
(2.36%)
189.700 USD
AZN
2.040
(2.58%)
81.200 USD
B
BNTX
-5.530
(-6.42%)
80.570 USD
GSK
0.865
(2.23%)
39.650 USD
I
INO
-0.670
(-6.28%)
10.000 USD
JNJ
2.930
(1.86%)
160.770 USD
MRK
0.680
(0.60%)
113.800 USD
MRNA
-25.020
(-20.99%)
94.160 USD
PFE
0.115
(0.38%)
30.650 USD
V
VXRT
-0.01170
(-1.74%)
0.65890 USD

الأخبار

المقالات

العنوان: Novavax

القطاع: Healthcare
الصناعة: Biotechnology
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.